These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 32213649

  • 1. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B, Meral R, Rus D, Hench R, Neidert AH, DiPaola F, Westerhoff M, Taylor SI, Oral EA.
    Endocrinol Diabetes Metab Case Rep; 2020 Mar 25; 2020():. PubMed ID: 32213649
    [Abstract] [Full Text] [Related]

  • 2. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.
    J Clin Invest; 2018 Aug 01; 128(8):3504-3516. PubMed ID: 29723161
    [Abstract] [Full Text] [Related]

  • 3. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M.
    Front Endocrinol (Lausanne); 2021 Aug 01; 12():690996. PubMed ID: 34135866
    [Abstract] [Full Text] [Related]

  • 4. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1511-1519. PubMed ID: 28324110
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.
    Clin Endocrinol (Oxf); 2016 Jul 01; 85(1):137-49. PubMed ID: 26589105
    [Abstract] [Full Text] [Related]

  • 6. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'.
    Adachi M, Muroya K, Hanakawa J, Asakura Y.
    Endocr J; 2021 Apr 28; 68(4):399-407. PubMed ID: 33229817
    [Abstract] [Full Text] [Related]

  • 7. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
    Rodriguez AJ, Mastronardi CA, Paz-Filho GJ.
    Ther Clin Risk Manag; 2015 Apr 28; 11():1391-400. PubMed ID: 26396524
    [Abstract] [Full Text] [Related]

  • 8. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T, Cochran E, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2015 May 28; 100(5):1802-10. PubMed ID: 25734254
    [Abstract] [Full Text] [Related]

  • 9. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.
    Endocr Pract; 2011 May 28; 17(6):922-32. PubMed ID: 22068254
    [Abstract] [Full Text] [Related]

  • 10. Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.
    Santos JL, Cortés VA.
    Obes Rev; 2021 Jan 28; 22(1):e13114. PubMed ID: 33030294
    [Abstract] [Full Text] [Related]

  • 11. Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy.
    Vieira DB, Antel J, Peters T, Miehle K, Stumvoll M, Hebebrand J, Schlögl H.
    Obes Facts; 2022 Jan 28; 15(5):685-693. PubMed ID: 36037795
    [Abstract] [Full Text] [Related]

  • 12. Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement.
    Ishida E, Horiguchi K, Matsumoto S, Ozawa A, Sekiguchi S, Yamada E.
    Diabetol Int; 2024 Apr 28; 15(2):290-296. PubMed ID: 38524924
    [Abstract] [Full Text] [Related]

  • 13. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C, Fetita S, Boudou P, Tchankou C, Deville L, Riveline J, Young J, Mathivon L, Travert F, Morin D, Cahen J, Lascols O, Andreelli F, Reznik Y, Mongeois E, Madelaine I, Vantyghem M, Gautier J, Vigouroux C.
    Diabetes Obes Metab; 2016 Jul 28; 18(7):693-7. PubMed ID: 26584826
    [Abstract] [Full Text] [Related]

  • 14. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
    Lebastchi J, Ajluni N, Neidert A, Oral EA.
    J Clin Endocrinol Metab; 2015 Nov 28; 100(11):3967-70. PubMed ID: 26390101
    [Abstract] [Full Text] [Related]

  • 15. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy.
    Simha V.
    Expert Rev Endocrinol Metab; 2014 May 28; 9(3):205-212. PubMed ID: 30736159
    [Abstract] [Full Text] [Related]

  • 16. Metreleptin: first global approval.
    Chou K, Perry CM.
    Drugs; 2013 Jun 28; 73(9):989-97. PubMed ID: 23740412
    [Abstract] [Full Text] [Related]

  • 17. Leptin Decreases Gluconeogenesis and Gluconeogenic Substrate Availability in Patients With Lipodystrophy.
    Quaye E, Chacko S, Startzell M, Brown RJ.
    J Clin Endocrinol Metab; 2023 Dec 21; 109(1):e209-e215. PubMed ID: 37515588
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H, Vantyghem MC, Nobécourt E, Andreelli F, Archambeaud F, Bismuth E, Briet C, Cartigny M, Chevalier B, Donadille B, Daguenel A, Fichet M, Gautier JF, Janmaat S, Jéru I, Legagneur C, Leguier L, Maitre J, Mongeois E, Poitou C, Renard E, Reznik Y, Spiteri A, Travert F, Vergès B, Zammouri J, Vigouroux C, Vatier C.
    Diabetes Obes Metab; 2022 Aug 21; 24(8):1565-1577. PubMed ID: 35445532
    [Abstract] [Full Text] [Related]

  • 19. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Gorden P.
    Endocrine; 2018 Jun 21; 60(3):479-489. PubMed ID: 29644599
    [Abstract] [Full Text] [Related]

  • 20. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R, Malandrino N, Walter M, Neidert AH, Muniyappa R, Oral EA, Brown RJ.
    J Clin Endocrinol Metab; 2022 Mar 24; 107(4):e1739-e1751. PubMed ID: 34677608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.